radiopharmaceuticals

News

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

News

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.

News

Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.

News

This week's round-up of private financings in the biotech arena features AdvanCell, alongside Draig, Drug Farm, MindRank AI, and Alchemab.

Oncology

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.